MM Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361–398.
H Organic anion transporter family: current knowledge. J Pharmacol Sci. 2006;100: 411–426.
M The bile salt export pump: molecular properties, function and regulation. Pflugers Arch. 2004;449: 123–131.
J Decontamination and detoxification strategies for the Fusarium mycotoxin deoxynivalenol in animal feed and the effectives of microbial biodegradation. Food Add Contam. 2010;27: 510–520.
DG Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010;70: 645–655.
AE Regulation of tight-junction permeability during nutrient absorption across the intestinal epithelium. Annu Rev Nutr. 1995;15: 35–55.
et al. Expression of multiple cytochrome P450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol. 2001;116: 541–548.
P Pore formation by the matrix protein (porin) to Escherichia coli in planar bilayer membranes. Ann NY Acad Sci. 1980;358: 13–24.
TG ABCC6 and pseudoxanthoma elasticum. Pflugers Arch. 2007;453: 685–691.
R High-affinity nasal extraction of vinyl acetate vapor is carboxylesterase dependent. Inhal Toxicol. 1999;11: 927–941.
TS Mechanism of enhanced drug effects produced by dilution of the oral dose. Toxicol Appl Pharmacol. 1971;19: 164–168.
N, van de Wetering
K MRP2 and 3 in health and disease. Cancer Lett. 2006;234: 51–61.
BR Oral absorption and disposition kinetics of lidocaine hydrochloride in dogs. J Pharmacol Exp Ther. 1970; 174:1–8.
Jr Methods for in vitro percutaneous absorption studies. I. Comparison with in vivo results. Toxicol Appl Pharmacol. 1982;62: 474–480.
EJ Gastrointestinal and dermal absorption: interspecies differences. Drug Metab Rev. 1984;15: 1013–1032.
MN Metabolic disposition of antihyperlipidemic agents in man and laboratory animals. Drug Metab Rev. 1980;11: 291–323.
Y Multi-specific organic anion transporter (cMOAT) is responsible for the biliary excretion of the camptothecin derivative irinotecan, CPT-11 and its metabolites in rats. J Pharmacol Exp Ther. 1997;281: 304–314.
TW Metal toxicity in the central nervous system. Environ Health Perspect. 1987;75: 59–64.
W The blood-brain barrier and cancer: transporters, treatment and trojan horses. Clin Cancer Res. 2007;13: 1663–1674.
CG, Rudi de Waart
IG, Oude Elferink
RPJ Increased bioavailability of the food-derived carcinoge 2-amino-1-methyl-6-phenylimidazo[4,5]pyridine in MRP2-deficient rats. Mol Pharmacol. 2001;59: 974–980.
et al. Multiorgan transplacental and neonatal carcinogenicity of 3′-axido-3′-deoxythymidine in mice. Toxicol Appl Pharmacol. 1999;161: 82–99.
HO Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82: 377–390.
JJ Absorption of the adrenergic-blocking agent, nadol, by mice, rats, hamsters, rabbits, dogs, monkeys and man: unusual species differences. Xenobiotica. 1978;8: 503–510.
PH Skin permeability theory in relation to measurements of percutaneous absorption in toxicology. In: Marzulli FN, Maibach HI, eds. Dermatotoxicology. 2nd ed. Washington/New York/London: Hemisphere; 1983:91–116.
KC Enterohepatic circulation of indomethacin and its role in intestinal irritation. Biochem Pharmacol. 1975;24: 1749–1754.
AM What can comparative studies of placental structure tell us?—A review. Placenta. 2004;25(suppl A):S3–S9.
JWA The distribution of some commonly used drugs in human breast milk. Drug Metab Rev. 1983;14: 653–686.
LS Comparative effects of iron deficiency induced by bleeding and low-iron diet on the intestinal absorptive interactions of iron, cobalt, manganese, zinc, lead and calcium. J Nutr. 1980;110: 1754–1763.
PU Factors affecting the oral up-take and translocation of polystyrene nanoparticles: histological and analytical evidence. J Drug Target. 1995;3: 65–70.
CS Intestinal interactions of lead and calcium. Neurotoxicology. 1992;13: 799–807.
FH Placental transporters relevant to drug disposition across the maternal-fetal interface. J Pharmacol Exp Ther. 2000;294: 413–420.
SJ Elimination of persistent toxicants from the human body. Human Exp Toxicol. 2011;30: 3–18.
C Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica. 2008;38: 778–801.
PJ Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 2004;447: 653–665.
SP Phospholipidosis as a function of basicity, lipophilicity and volume of distribution of compounds. Chem Res Toxicol. 2010;23: 749–755.
EA The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflugers Arch. 2004;447: 465–468.
T Cytotoxicity of antiviral nucleotides adefovir and cidofovir induced by the expression of the human renal organic anion transporter I. J Am Soc Nephrol. 2000;11: 383–393.
et al. Species differences in the transport activity for organic anions across the bile canalicular membrane. J Pharmacol Exp Ther. 1999;290: 1324–1330.
P Factors affecting the storage and excretion of toxic lipophilic xenobiotics. Lipids. 2001;36: 1289–1305.
AT Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol. 1990;42: 821–826.
J Skin penetration and metabolism of topically applied chemicals in six mammalian species, including man: an in vitro study with benzo(a)pyrene and testosterone. Toxicol Appl Pharmacol. 1985;81: 502–516.
JA Carcinogenicity of formaldehyde in rats and mice after long-term inhalation exposure. Cancer Res. 1983;43: 4382–4392.
LM Xenobiotic, bile acid and cholesterol transporters: function and regulation. Pharmacol Rev. 2010;62: 1–96.
J Role of metallothionein in cadmium-induced hepatotoxicity and nephrotoxicity. Drug Metab Rev. 1997;29: 79–102.
H Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol Sci. 2008;101: 186–196.
DW Biliary excretion of lead in rats, rabbits and dogs. Toxicol Appl Pharmacol. 1974;29: 434–446.
AL Regulation of hepatic transporters by xenobiotic receptors. Curr Drug Metab. 2005;6: 309–328.
JB Mechanisms of bile formation, hepatic uptake, and biliary excretion. Pharmacol Rev. 1984;36: 1–67.
Z-S ABCC10, ABCC11 and ABCC12. Pflugers Arch-Eur J Physiol. 2007;453: 675–684.
Y Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx. 2005;2: 73–85.
Y In vitro-invio extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet. 2009;24: 37–52.
et al. Penetration and storage of particles in human skin: perspectives and safety aspects. Eur J Pharm Biopharm. 2011;77: 465–468.
D P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol Appl Pharmacol. 1997;143: 357–365.
et al. Placental p-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol. 1998;12: 457–463.
LD α2u-Globulin nephropathy. In: Schnellman RG, ed. Comprehensive Toxicology. 2nd ed. New York: Elsevier; 2010:507–521.
D Induction and inhibition of mouse cytochrome P450 2B enzymes by musk xylene. Toxicol Appl Pharmacol. 1997;142: 169–177.
B Transition of nitro musks and polycyclic musks into human milk. Adv Exp Med Biol. 2000;478: 289–305.
R Placental structure: in a comparative aspect. Exp Clin Endocrinol. 1994;102: 122–134.
W Comparative studies of absorption of heavy metals in vivo and in vitro. Arch Pharmacol Exp Pathol. 1969;263: 275–276.
SPC Multidurg resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;204: 216–237.
KK Toxicokinetics of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in female Sprague-Dawley rats including placental and lactational transfer to fetuses and neonates. Fundam Appl Toxicol. 1995;27: 70–76.
L An evaluation of mathematical models for predicting skin permeability. J Pharm Sci. 2008;97: 585–598.
JH Species similarities and differences in pharmacokinetics. Drug Metab Dispos. 1995;23: 1008–1021.
JH Tissue distribution and pharmacodynamics: a complicated relationship. Curr Drug Metab. 2006;7: 39–65.
PJ Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46: 3–26.
et al. Characterization of organic anion transporting polypeptide 1b2-null mice: essential role in hepatic uptake/toxicity o phalloidin and microcystin-LR. Toxicol Sci. 2008;103: 35–45.
TW The effect of oral doses of a polythiol resin on the excretion of methylmercury in mice treated with cystein, d-penicillamine or phenobarbitone. Chem Biol Interact. 1976;14: 325–335.
IV Calculation of molecular lipophilicity: state-of-the-art and comparison of Log P methods on more than 96,000 compounds. J Pharm Sci. 2009;98: 861–893.
J Health implications of exposure to environmental nitrogenous compounds. Toxicol Rev. 2003;22:41–51.
DS Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharm Sci. 2010;31: 246–254.
Y Impact of drug transporter studies on drug discovery and development. Pharmacol Rev. 2003;55: 425–461.
M, van Staden
et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010;118: 485–500.
D Placental transport. In: Knobel E, Neill JD, eds. The Physiology of Reproduction. New York, NY: Raven Press; 1994:813–861.
O Human placenta: a human organ for developmental toxicology research and biomonitoring. Placenta. 2005;26: 361–371.
N Toxic potential of materials at the nanolevel. Science. 2006;311: 622–627.
JA Transplacental hormonal carcinogenesis: diethylstilbestrol as an example. Prog Clin Biol Res. 1996;394: 131–147.
JI The safety of nanosized particles in titanium dioxide and zinc oxide-based suncreens. J Am Acad Dermatol. 2009;61: 685–692.
Q Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab. 2010;11: 603–617.
J Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect. 2005;113: 823–839.
CJ Gastroenterologic response to environmental agents—absorption and interactions. In: Lee DHK, ed. Handbook of Physiology. Section 9: Reactions to Environmental Agents. Bethesda, MD: American Physiological Society; 1977:349–374.
JN Skin absorption and human risk assessment. Chem Biol Interact. 2002;140: 19–34.
S The role of the placenta in fetal exposure to xenobiotics: importance of membrane transporters and human models for transport studies. Drug Metab Dispos. 2010;38: 1623–1635.
JA Dinitrotoluene: acute toxicity, oncogenicity, genotoxicity and metabolism. CRC Crit Rev Toxicol. 1984;13: 217–234.
G Organic anion transporters of the SLC22 family: biopharmaceutical, physiological and pathological roles. Pharm Res. 2007;24: 9181–2004.
HI Dermal absorption of 2,4-D: a review of species differences. Regul Toxicol Pharmacol. 2005;41:82–91.
A The effect of diet on mammalian gut flora and its metabolic activities. CRC Crit Rev Toxicol. 1985;16: 31–103.
J Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates. Expert Opin Drug Metab Toxicol. 2005;1: 409–427.
SG Assessing liver function. Curr Opin Crit Care. 2007;13: 207–214.
LS Passage of drugs across body membranes. Pharmacol Rev. 1962;74: 501–530.
JJM, van Tellingen
et al. Disruption of the mouse mdr1a p-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell. 1994;47: 491–502.
EW The so-called habituation to arsenic: variation in the toxicity of arsenious oxide. J Pharmacol Exp Ther. 1923;20: 181–203.
RE The deposition of propranolol: I. Elimination during oral absorption in man. Pharmacology. 1972;7: 159–168.
Y Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annu Rev Pharmacol Toxicol. 2005;45: 689–723.
DN A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics. 1956;18: 614–625.
HW Observations on the flora of the alimentary tract of animals and factors affecting its composition. J Pathol Bacteriol. 1965;89: 95–107.
SE Nanotechnology safety concerns revisited. Toxicol Sci. 2008;101: 4–21.
KS The Caco-2 cell monolayer: usefulness and limitations. Expert Opin Drug Metab Toxicol. 2008;4: 395–411.
KLR Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev. 2010;42: 446–471.
KKA Comparative study of griseofulvin-14C metabolism in the rat and rabbit. Biochem Pharmacol. 1967;16: 2405–2411.
JA Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43: 487–514.
I Oral drug delivery using intestinal OATP transporters. Adv Drug Deliv Rev. 2012;64: 508–514.
MP Arsenic, stem cells and the developmental basis of adult cancer. Toxicol Sci. 2011;120(suppl 1):S192–S203.
K ABC proteins protect the human body and maintain optimal health. Biosci Biotechnol Biochem. 2011;75: 401–409.
Van den Berg
K Transfer of polychlorinated dibenzo-p-dioxins and dibenzofurans to fetal and neonatal rats. Fundam Appl Toxicol. 1987;9: 635–644.
AH The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci. 2006;27: 10–16.
et al. The sequence of the human genome. Science. 2001;291: 1304–1351.
AH Physiological and pharmacological roles of ABCG2 (BCRP): recent findings in Abcg2 knockout mice. Adv Drug Deliv Rev. 2009;61: 14–25.
et al. Carcinogen and anticancer drug transport by Mrp2 in vivo: Studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther. 2006;318: 319–327.
Y Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. Mol Pharmacol. 2003;63: 844–848.
BA Transplacental carcinogenesis of inorganic arsenic in drinking water: induction of hepatic, ovarian, pulmonary and adrenal tumors in mice. Toxicol Appl Pharmacol. 2003;186: 7–17.
AG Species-specific uncertainty factors for compounds eliminated principally by renal excretion in humans. Food Chem Toxicol. 2004;42: 261–274.
HI Animal models for percutaneous absorption. In: Wang RGM, Knaak JB, Maibach HI, eds. Health Risk Assessment—Dermal and Inhalation Exposure and Absorption of Toxicants. Boca Raton: CRC Press; 1993:89–103.
GL, van der Valk
et al. Multidrug resistance protien 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage. J Exp Med. 1998;188: 797–808.
BW Penetration enhancers. Adv Drug Deliv Rev. 2004;56: 603–618.
JT Determinants and consequences of drug excretion in breast milk. Drug Metab Rev. 1983;14: 619–652.
TH Mechanisms of Absorption. Philadelphia: WB Saunders; 1962:40–68.
CJ Interaction between anticonvulsants and human placental carnitine transporter. Epilepsia. 2004;45: 204–210.
J Intestinal brush border transport mechanism of 5-fluorocuracil in rats. Biol Pharm Bull. 1996;19: 94–99.
Q Breast cancer resistance protein limits fetal distribution of nitrofurantoin in the pregnant mouse. Drug Metab Dispos. 2007;35: 2154–2158.
MF Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin Pharmacol Ther. 2011;89: 798–805.